<DOC>
	<DOCNO>NCT02341378</DOCNO>
	<brief_summary>To assess efficacy safety intra-articular injection TissueGene-C patient degenerative arthritis knee</brief_summary>
	<brief_title>Efficacy Safety Study TissueGene-C Degenerative Arthritis</brief_title>
	<detailed_description>TissueGene-C biological new drug consist non-transduced chondrocytes transduce chondrocytes express Transforming Growth Factor ( TGF ) -b1 regenerate damage cartilage . During clinical trial Phase 2A , compare low dose high dose TissueGene-C 6 month trial 28 outpatient degenerative arthritis . The patient randomize two dose level TisssueGene-C 1:1 ratio , monitor record alleviating symptom , sport activity , function knee , presence adverse event .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Osteoarthritis</mesh_term>
	<criteria>1 . Male female , age 45 year 2 . With grade 4 degenerative arthritis knee [ base International Cartilage Repair Society ( ICRS ) evaluation criterion MRI result ] 3 . With less 6 cm2major lesion 4 . With major lesion ( grade 4 ) concentrate one section knee consider main cause clinical symptom 5 . Unresponsive conventional symptomatic treatment 6 . Healthy major physical examination , hematology , serum chemistry , urine test finding significant medical history 7 . Agreed use effective contraceptive method study period 8 . Voluntarily agree participate study sign Informed Consent Form 1 . Abnormal screen laboratory test ( hematology , serum , urine test ) find 2 . Took antiinflammatory medication ( prescribed overthecounter ) , include natural medicine , within 14 day injection investigational product 3 . Took antirheumatic drug ( e.g. , methotrexate antimetabolite ) within three month enrollment study 4 . Has history drug abuse within one year enrolment , positive result urine drug test serum alcohol test screen visit 5 . Received injection target knee within two month enrollment study 6 . Pregnant breastfeed female 7 . With another joint disease apart degenerative arthritis ( e.g. , systemic rheumatic inflammatory disease associate knee chondrocalcinosis , hemachromatosis , inflammatory arthritis , necrosis trochanter , Paget 's disease adjacent joint femur tibia , ochronosis , hemophilic arthropathy , infectious arthritis , Charcot 's disease knee joint , villonodular synovitis , synovial chondroma ) 8 . With current infectious disease , include HIV hepatitis 9 . Has follow clinically significant disease : heart disease [ e.g. , myocardial infarction , arrhythmia , serious heart disease , coronary artery bypass graft ( CABG ) ] kidney disease ( e.g. , chronic renal failure , glomerulonephritis ) liver disease ( e.g. , liver cirrhosis , fatty liver , acute chronic liver disease ) endocrine disease ( e.g. , hyperthyroidism , hypothyroidism , thyroiditis , diabetes insipidus , Cushing 's disease ) insulindependent diabetes mellitus medical history current malignant tumor In particular , tumor TissueGeneC may aggravate screen use follow test : Leukemia : White Blood Cell level hematology Osteochondroma , Chondromas , Chondroblastoma , Chondromyxoid fibroma , Chondrosarcoma : Alkaline phosphatase level hematology 10 . Participated another clinical trial ( use investigational drug medical device ) within 30 day enrollment study 11 . Considered investigator inappropriate participation study</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>chondrocyte cell</keyword>
	<keyword>Osteoarthritis</keyword>
	<keyword>gene therapy</keyword>
</DOC>